High Expression of Ubiquitin C-terminal Hydrolase L1 Is Associated With Poor Prognosis in Endometrial Cancer Patients

被引:8
作者
Nakao, Kohshiro [1 ]
Hirakawa, Takashi [1 ]
Suwa, Hiroto [1 ]
Kogure, Kayoko [1 ]
Ikeda, Sadatomo [1 ]
Yamashita, Soichi [1 ]
Minegishi, Takashi [1 ]
Kishi, Hiroshi [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Obstet & Gynecol, Maebashi, Gunma 3718511, Japan
关键词
Endometrial cancer; Metastasis; Prognostic factor; UCHL1; GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-III TRIAL; INTERMEDIATE-RISK; PROTEASOME INHIBITOR; L1CAM EXPRESSION; RANDOMIZED-TRIAL; CARCINOMA; RADIOTHERAPY; PGP9.5; CELLS;
D O I
10.1097/IGC.0000000000001201
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective The ubiquitin C-terminal hydrolase L1 (UCHL1) plays a key role in tumor invasion and metastasis. Ubiquitin C-terminal hydrolase L1 is overexpressed in various cancers and reported to be correlated with a poor prognosis. The objective of this study was to determine the prognostic significance of UCHL1 in endometrial cancer. Methods The expression of UCHL1 in endometrial cancer was assessed using quantitative reverse transcription polymerase chain reaction and immunohistochemistry in 56 and 215 resected tumor specimens, respectively. Results The 4-year survival rates of the high UCHL1 messenger RNA expression group and high UCHL1 protein expression group were 78% and 71%, respectively, compared with 96% and 95% for the low UCHL1 messenger RNA expression group and low UCHL1 protein expression group, respectively. Kaplan-Meier and log-rank tests indicated a significant correlation between expression of UCHL1 and disease-free survival and overall survival. Moreover, multivariate stepwise Cox proportional hazard regression model analysis showed that UCHL1 was a significant independent marker for predicting a poor disease-free survival and overall survival. In 43 patients with metastatic lesions, immunohistochemical analysis of metastatic lesions revealed that the recurrence rate and mortality rate were 62% and 41%, respectively, in 29 UCHL1-positive patients and 36% and 29%, respectively, in 14 UCHL1-negative patients. Conclusions The results of this study suggest that high UCHL1 expression is a strong marker of poor prognosis of endometrial cancer. Furthermore, we suggest that UCHL1 may be involved in the development of distant metastasis in endometrial cancer.
引用
收藏
页码:675 / 683
页数:9
相关论文
共 41 条
  • [21] PROGNOSTIC VALUE OF EPIDERMAL GROWTH-FACTOR RECEPTOR EXPRESSION IN ENDOMETRIOID ENDOMETRIAL CARCINOMA
    NIIKURA, H
    SASANO, H
    MATSUNAGA, G
    WATANABE, K
    ITO, K
    SATO, S
    YAJIMA, A
    [J]. HUMAN PATHOLOGY, 1995, 26 (08) : 892 - 896
  • [22] Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
    Nout, R. A.
    Smit, V. T. H. B. M.
    Putter, H.
    Juergenliemk-Schulz, I. M.
    Jobsen, J. J.
    Lutgens, L. C. H. W.
    van der Steen-Banasik, E. M.
    Mens, J. W. M.
    Slot, A.
    Kroese, M. C. Stenfert
    van Bunningen, B. N. F. M.
    Ansink, A. C.
    van Putten, W. L. J.
    Creutzberg, C. L.
    [J]. LANCET, 2010, 375 (9717) : 816 - 823
  • [23] High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma
    Oda, K
    Stokoe, D
    Taketani, Y
    McCormick, F
    [J]. CANCER RESEARCH, 2005, 65 (23) : 10669 - 10673
  • [24] Silencing of the UCHL1 gene in human colorectal and ovarian cancers
    Okochi-Takada, Eriko
    Nakazawa, Kazuyuki
    Wakabayashi, Mika
    Mori, Akiko
    Ichimura, Shizue
    Yasugi, Toshiharu
    Ushijima, Toshikazu
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (06) : 1338 - 1344
  • [25] Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study
    Randall, ME
    Filiaci, VL
    Muss, H
    Spirtos, NM
    Mannel, RS
    Fowler, L
    Thigpen, JT
    Benda, JA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 36 - 44
  • [26] Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer
    Santin, AD
    Bellone, S
    Siegel, ER
    Palmieri, M
    Thomas, M
    Cannon, MJ
    Kay, HH
    Roman, JJ
    Burnett, A
    Pecorelli, S
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (03) : 813 - 818
  • [27] Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients
    Schroeder, Christine
    Milde-Langosch, Karin
    Gebauer, Florian
    Schmid, Katharina
    Mueller, Volkmar
    Wirtz, Ralph M.
    Meyer-Schwesinger, Catherine
    Schlueter, Hartmut
    Sauter, Guido
    Schumacher, Udo
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (10) : 1745 - 1755
  • [28] Localization of ubiquitin C-terminal hydrolase L1 in mouse ova and its function in the plasma membrane to block polyspermy
    Sekiguchi, Satoshi
    Kwon, Jungkee
    Yoshida, Etsuko
    Hamasaki, Hiroko
    Ichinose, Shizuko
    Hideshima, Makoto
    Kuraoka, Mutsuki
    Takahashi, Akio
    Ishii, Yoshiyuki
    Kyuwa, Shigeru
    Wada, Keiji
    Yoshikawa, Yasuhiro
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2006, 169 (05) : 1722 - 1729
  • [29] GPR30: a novel indicator of poor survival for endometrial carcinoma
    Smith, Harriet O.
    Leslie, Kimberly K.
    Singh, Meenakshi
    Qualls, Clifford R.
    Revankar, Chetana M.
    Joste, Nancy E.
    Prossnitz, Eric R.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 196 (04) : 386.e1 - 386.e11
  • [30] The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network
    Song, Min Sup
    Salmena, Leonardo
    Carracedo, Arkaitz
    Egia, Ainara
    Lo-Coco, Francesco
    Teruya-Feldstein, Julie
    Pandolfi, Pier Paolo
    [J]. NATURE, 2008, 455 (7214) : 813 - U11